论文部分内容阅读
目的探讨通心络联合美托洛尔治疗老年冠心病的临床疗效及对患者心功能的影响,为指导临床用药提供参考。方法选取2015年1月—2016年1月镇平县人民医院收治的老年冠心病患者96例,将其随机分为观察组和对照组,每组48例。对照组单用美托洛尔治疗,观察组在对照组治疗基础上加用通心络治疗。对比两组治疗8周后临床疗效、心功能改善情况及不良反应发生情况。结果观察组治疗总有效率为91.67%明显高于对照组的77.08%,差异有统计学意义(P<0.05);观察组左心室收缩末期内径(LVESD)与左心室舒张末期内径(LVEDD)较对照组明显降低,心排血量(CO)较对照组明显升高,差异有统计学意义(P<0.05);治疗期间,对照组未发生不良反应,观察组仅出现1例胃部不适,改餐后服药,症状消失。结论通心络联合美托洛尔治疗冠心病是一种安全高效的治疗方式,有助于改善患者心功能,提高临床疗效。
Objective To investigate the clinical efficacy of Tongxinluo combined with metoprolol in the treatment of elderly patients with coronary heart disease and its influence on cardiac function in order to provide reference for clinical use. Methods 96 elderly patients with coronary heart disease admitted from January 2015 to January 2016 in Zhenping County People’s Hospital were selected and randomly divided into observation group and control group with 48 cases in each group. The control group was treated with metoprolol alone. The observation group was treated with Tongxinluo on the basis of the control group. After 8 weeks of treatment, the clinical curative effect, the improvement of cardiac function and the incidence of adverse reactions were compared. Results The total effective rate in the observation group was 91.67%, which was significantly higher than that in the control group (77.08%) (P <0.05). Compared with the control group, the left ventricular end-systolic diameter (LVESD) and the left ventricular end-diastolic diameter The control group was significantly lower, cardiac output (CO) was significantly higher than the control group, the difference was statistically significant (P <0.05); during the treatment, no adverse reactions in the control group, the observation group showed only 1 case of stomach discomfort, Change the food after meals, the symptoms disappear. Conclusion Tongxinluo combined with metoprolol in the treatment of coronary heart disease is a safe and efficient treatment, which can help improve the patient’s cardiac function and improve the clinical efficacy.